Anti-Atezolizumab ELISA Assay Kit

$1,450.00

The Anti-Atezolizumab ELISA Assay Kit is intended as an analytical tool for quantitative determination of Anti-Atezolizumab in serum, plasma, and cell culture supernatant.

SKU: KBI2027 Category:

Anti-Atezolizumab ELISA Assay Kit

The Anti-Atezolizumab ELISA Assay Kit is For Research Use Only

Size: 12×8 wells
Sensitivity: 10 ng/ml
Standard Range: 10-640 ng/ml
Incubation Time: 2.25 hours
Sample Type: Serum, Plasma, Cell Culture Supernatants
Sample Size: 100 µl
Alternative Name: Tecentriq


Assay Background

Atezolizumab (trade name Tecentriq) is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). In 2015, it was in clinical trials as an immunotherapy for several types of solid tumors. It was under investigation by Genentech/Roche. In April 2016, Roche announced that atezolizumab had been granted fast track status for lung cancer by the FDA. In May 2018, Tecentriq was in combination with Avastin and standard chemotherapy for some patients with lung cancer was granted priority review. Anti-Drug Antibodies (ADA) may induce unwanted side effects in biopharmaceuticals. Hence, ADA has been subjected to increase in scrutiny by the regulatory authorities using immunogenicity safety studies. ADA has been observed in pre-clinical and clinical studies, resulting in significant changes in toxicology, pharmacokinetics and efficacy. These effects result from the generation of drug-induced (neutralizing) autoantibodies against Atezolizumab and can be responsible for allergic reaction, or even anaphylactic shock. This ELISA kit detects antibodies for Anti-Atezolizumab and may be used for monitoring immunogenicity.


Related Products

Atezolizumab ELISA Assay Kit
Anti-Daratumumab (Darzalex) ELISA Assay Kit
Anti-Rituximab ELISA Assay Kit

Additional Information

Assay Principle


The method employs the quantitative sandwich enzyme immunoassay technique. Atezolizumab is pre-coated onto microwells. Samples and standards are pipetted into microwells and antibodies to Atezolizumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated Atezolizumab is pipetted and incubated. After washing microwells in order to remove any nonspecific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Anti-Atezolizumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

Documents

Product Documents